AFMD Affimed N.V.

+0.02  (+1%)
Previous Close 2.7
Open 2.7
Price To Book 4.61
Market Cap 169,837,379
Shares 62,440,213
Volume 400,898
Short Ratio
Av. Daily Volume 951,765

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
Phase 2a ongoing.
Hodgkin Lymphoma - Cancer
Phase 2 interim efficacy data due mid-2020. Top-line data due 2021.
CD30-positive peripheral T cell lymphoma (PTCL)
Phase 1 program terminated - noted May 22, 2019.
Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)

Latest News

  1. Edited Transcript of AFMD earnings conference call or presentation 7-Aug-19 12:30pm GMT
  2. Affimed N.V. (AFMD) Q2 2019 Earnings Call Transcript
  3. Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
  4. Affimed Reports Second Quarter 2019 Financial and Operational Results
  5. Earnings Outlook For Affimed
  6. Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019
  7. Is Affimed N.V.'s (NASDAQ:AFMD) CEO Salary Justified?
  8. All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy
  9. Affimed Added to the Russell 2000®, 3000® and Microcap Indexes
  10. Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019
  11. The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
  12. Edited Transcript of AFMD earnings conference call or presentation 22-May-19 12:30pm GMT
  13. Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland
  14. Affimed Announces Annual General Meeting of Shareholders
  15. Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expression Technology
  16. Affimed to Present at the Jefferies 2019 Healthcare Conference
  17. Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1
  18. Affirmed Therapeutics (AFMD) Beats Q1 Earnings and Revenue Estimates
  19. Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10%